Natco Pharma gets CDSCO emergency use nod for Baricitinib for treating COVID
Hyderabad: Pharma major, Natco Pharma Limited, announced that the company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients. "Natco will be requesting a Compulsory License based on emergency...
Hyderabad: Pharma major, Natco Pharma Limited, announced that the company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.
"Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic," the company stated.
The company is ready to launch the product this week, so as to make the product available to suffering patients across India.
Read also: Natco Pharma seeks CDSCO emergency nod for Covid drug Molnupiravir
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
